A common genetic disorder known as hypertrophic cardiomyopathy (HCM) is distinguished by abnormal heart thickening. Traditional treatments frequently fail to meet the demands of individuals who have severe symptoms and obstructive consequences. Mavacamten, a myosin inhibitor, has shown promise in improving the quality of life, functional ability, and clinical outcomes for those with obstructive HCM. This systematic review examined the clinical outcomes associated with mavacamten. Data gathering adhered to the Cochrane Handbook for Systematic Reviews of Interventions (Version 6) and preferred reporting items for systematic reviews and meta-analyses criteria, with an emphasis on study characteristics, patient demographics, and mavacamten doses. Maximum wall thickness, left ventricular mass index (LVMI), left atrial volume index (LAVI), peak oxygen consumption, and N-terminal pro-B-type natriuretic peptide were also significant out-come markers. A total of 532 studies were initially discovered, five of which met the inclusion criteria. The sample size ranged from 54 to 251 people, with the majority aged 51 to 61 years. The study found no statistically significant changes in outcomes for LVMI (pooled mean difference 0.55, p = 0.85), LAVI (pooled mean difference −1.48, p = 0.16), or maximal wall thickness (pooled mean difference 0.12, p = 0.75). A trend toward a decrease in the septal E/e’ ratio was seen (pooled mean difference −1.98, p = 0.24), however, it was not statistically significant. These findings showed mavacamten’s potential to improve diastolic function, necessitating future research with larger sample sizes and longer follow-up timeframes.
Key words: Hypertrophic cardiomyopathy, mavacamten, myosin inhibitor, systematic review, cardiac outcomes
|
